#111 Welcome to Mednow It's like having a pharmacy right in your pocket. to Get Started Let's get you logged in. Email Address Password Remember me mednow Sign in → Forgot Password? have an account? Register mednow Canada's Virtual Pharmacy "Driving digitalisation of retail pharmacy in Canada with proprietary technology and owned pharmacy distribution" TSX-V:MNOW OTC-QX: MDNWF October 21, 2022#2Notice and Disclaimer A final base shelf prospectus containing important information relating to the securities described in this presentation by Mednow Inc. ("Mednow", the "Company", "we", or "us") has been filed with the securities regulatory authorities in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario. A copy of the final base shelf prospectus, any amendment to the final base shelf prospectus and any applicable shelf prospectus supplement that has been filed, is required to be delivered with this presentation. This presentation does not provide full disclosure of all material facts relating to the securities offered. Investors should read the final base shelf prospectus, any amendment and any applicable shelf prospectus supplement for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.Prospective investors should be aware that the acquisition and disposition of the securities may have tax consequences both in the United States and in Canada. Such consequences for investors are not described fully herein. Prospective investors should read the tax discussion contained in any applicable prospectus supplement with respect to a particular offering of the securities. See "Certain Federal Income Tax Considerations" in the final base shelf prospectus. This presentation has been prepared for information purposes only and is not intended to form the basis of any investment decision. It does not constitute an offer invitation for the sale or purchase of any securities, businesses and/or assets or any recommendation or commitment by Mednow or any other person and neither this presentation, nor its contents nor any other written or oral information made available in connection with this presentation shall form the basis of any agreement or transaction. This presentation has been prepared without reference to your particular investment objectives, financial situation, risk profile or tolerance, tax position or particular needs. If you are in any doubt in relation to these matters, you should consult your financial and other advisers. The securities of Mednow have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under applicable state securities laws and, accordingly, the securities of Mednow may not be offered, sold, pledged or transferred, directly or indirectly in, into or within the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. NOTHING DESCRIBED IN THIS PRESENTATION NOR THE SECURITIES OF MEDNOW HAVE BEEN RECOMMENDED, APPROVED OR DISAPPROVED BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR BY THE SECURITIES REGULATORY AUTHORITY OF ANY STATE, PROVINCE OR ANY OTHER JURISDICTION, NOR HAS ANY SUCH SECURITIES REGULATORY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF ANY PROPOSED OFFER OF SECURITIES OR THE ACCURACY OR ADEQUACY OF THIS PRESENTATION. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. Except where otherwise indicated, the information contained in this presentation speaks as of the date hereof or as of the date at which such information is expressed to be stated, as applicable. Mednow disclaims any intention or obligation or undertaking to update or revise this information in light of new information, future events or otherwise, except as required by applicable law. Unless otherwise noted, all references to "$" or "Dollars" are to Canadian Dollars. Forward-Looking Information This presentation contains "forward-looking information" and "forward looking statements" for purposes of applicable Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations or assumptions regarding the future of our business, future plans and strategies, our operational results and other future conditions. Forward-looking statements can be identified by words such as "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "predict", "project", "seek", "target", "potential", "will", "would", "could", "should", "continue", "contemplate" and other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include all matters that are not historical facts, and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our operational and financial performance including revenue and gross margin forecasts performance, market opportunities, estimates relating to market growth, the intention to grow the business operations and expand into additional jurisdictions, expected benefits of recently completed acquisitions, planned activities of the Company, future outlook and goals, prospects, strategies and the industry in which we operate. Forward-looking statements are based on our current expectations, beliefs, assumptions, estimates and forecasts about the Company's business and the industry and markets in which it operates, including among others, assumptions relating to: (i) the ability of the Company to successfully expand into additional jurisdictions; (ii) that the telemedicine and pharmacy market will grow at the rate expected; (iii) the availability of financing: (iv) that third party contractors and supplies and regulatory approvals required to conduct the Company's planned activities will be available on reasonable terms and in a timely manner; (v) that general business, legislative and economic conditions will not change in a material adverse manner; (vi) that the Company will receive all approvals required to operate and grow its business as planned; (vii) that the Company will be successful in pursuing revenue, operational and other synergies with its recently completed acquisitions; and (viii) that COVID-19, the ongoing conflict in Eastern Europe, or other global events will not negatively impact the business or personnel of the Company. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. By their nature, forward-looking statements involve known and unknown risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the failure of the Company to realize the benefits of its expansion plans as expected; the inability of the Company to obtain the capital or approvals, permits or licenses required to achieve its business objectives; unanticipated costs; reliance on key management and other personnel; potential downturns in economic conditions; increased competition; failure to effectively synergize the operations of our recently completed acquisitions; changes in laws and regulations; impact of COVID-19 on the business and personnel of the Company; other risks associated with the Company's industry; and those described in greater detail under "Risk Factors" in the Company's final short form prospectus filed on July 15, 2022 on www.sedar.com under the Company's profile. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. This presentation also contains future-oriented financial information and financial outlook information (collectively, "FOFI") as defined under Canadian securities laws, prepared by Mednow's management about Mednow's reasonably estimated prospective results of operations, revenue, sales, and components thereof, all of which are subject to the same assumptions, risks factors, limitations and qualifications set forth in the above paragraphs. Readers are cautioned that FOFI are not guarantees of future performance, and should not be considered as such. There can be no assurance that the forward-looking statements or the FOFI contained in this presentation will prove to be accurate, as actual results and future events could differ materially from those anticipated in, or implied by such forward-looking statements and FOFI. Accordingly, readers should not place undue reliance on the forward-looking statements or FOFI contained in this presentation. Mednow and its management believe that FOFI has been prepared on a reasonable basis, reflecting management's best estimates and judgements. FOFI contained in this presentation were made as of the date of this presentation and is provided for the purpose of describing the belief Mednow's management of the anticipated effects of the financing on Mednow's business operations. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Additionally, any forward-looking statements that we make in this presentation speaks only as of the date of this presentation. Mednow does not undertake any obligation to publicly update or revise any forward-looking statements or FOFI other than as required under applicable securities laws. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data. Non-IFRS Measures and Non-IFRS Ratios This presentation refers to certain measures and ratios that are not recognized measures under International Financial Reporting Standards ("IFRS"). The following non-IFRS measures and non-IFRS ratios are used in this presentation: (i) gross margin % (net sales minus the cost of goods/services sold divided by net sales). These measures and ratios do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other issuers. Rather, these measures and ratios are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from Mednow's management's perspective. Accordingly, the non-IFRS measures and non-IFRS ratios disclosed in this presentation should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS and are not necessarily indicative of operating results presented under IFRS. These non-IFRS measures and non-IFRS ratios are used to provide investors with supplemental measures of our operating performance and thus highlight trends in Mednow's core business that may not otherwise be apparent when relying solely on IFRS measures. Market and Industry Data Market and industry data presented in this presentation (including estimates and projections relating to addressable markets) was obtained from third-party reports, publications, websites and other publicly available information or prepared by Mednow or on its behalf on the basis of its knowledge of the markets and industry in which it operates or plans to operate, including information provided by suppliers, partners, dealers and other industry participants. The accuracy and completeness of the market and industry data presented in this presentation are not guaranteed, and Mednow makes no representation or warranty, express or implied, as to the accuracy or completeness of such data. Although Mednow believes it to be reliable, it has not independently verified any of the data from third-party sources referred to in this presentation, analyzed or verified the underlying studies or relied upon or referred to by such sources, or ascertained the underlying market, industry and other assumptions relied upon by such sources. Market and industry data cannot be verified due to limits on the availability and reliability of data inputs, the voluntary nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey. This presentation is qualified in its entirety by reference to, and must be read in conjunction with, the information contained in the Company's final base shelf prospectus, any amendment to the final base shelf prospectus and any applicable shelf prospectus supplement. Neither the Company nor Gravitas Securities Inc., as agent, have authorized anyone to provide prospective purchasers with additional or different information. If anyone provides prospective purchasers with additional or different or inconsistent information, including information or statements in media articles about the Company, prospective purchasers should not rely on it. Prospective purchasers should not assume that the information contained in this presentation is accurate as of any date other than the date hereof, or where information is stated to be as of a date other than the date hereof, such other applicable date. An investment in the securities described herein is speculative and involves a high degree of risk. Prospective purchasers should carefully consider the risk factors described under "Risk Factors" in the Company's final base shelf prospectus and the applicable shelf prospectus supplement and any amendment before purchasing securities. Information has been incorporated by reference in the base shelf prospectus from documents filed with securities commissions or similar authorities in Canada. Copies of the documents incorporated therein by reference are available electronically at www.sedar.com.#3Company Overview • Mednow is striving to be an emerging Leader in Virtual Pharmacy with key market leading differentiators in patient experience, logistics, and speciality pharmacy capabilities. mednow • Current Virtual Pharmacy Utilization is very low in Canada (<1%).¹ However according to a recent study, post-pandemic, Canadians have express being open to using a virtual pharmacy. With few purely virtual national competitors, management believes the company is well positioned to become a market leader in the virtual pharmacy space.² The Pharmacy of the Future is Here • 9 owned pharmacy Urban Distribution Centers (including 1 pending licence approval) connect to patients via Proprietary Technology, provide same day delivery to a majority of Canadians: Toronto, London, Vancouver, Winnipeg, Calgary, Halifax, and Montreal, and have effective logistics. Vancouver ITSX-V: MNOW I OTC-QX: MDNWF Calgary Winnipeg London Toronto Montreal Dartmouth Hi, Ronald. How can we help you? Do you have a prescription at another pharmacy? If you have an active prescription or available refils, our team can transfer them for you. ✔Request a Transfer Upload a New Prescription Don't Have a Prescription? See a Clinician O Chat With Our Pharmacy What is the dispensing fee? In Home 10 g Orders Profile □ Proprietary Technology Virtual Pharmacy: Access a pharmacist, manage prescriptions and fill medications in Canada by phone or app, with free delivery. Specialty Pharmacy Services: Integrated care models focused on high cost medications. Wellness E-Commerce: Non-prescription items and wellness products. Doctor Services: Online (ON and BC) or at-home visits with doctor (GTA). Owned Pharmacy Distribution Pharmacy Distribution Centers Waiting for the pharmacy license approval 1. Based on management's current knowledge and reasonable belief 2. Maru Blu Research 15-minute online survey of 2,564 individuals living in Canada who are 25 years or older and geographically balanced. Surveys were completed between February 26 and March 14, 2022 3#4ET Jber TOTAL ATTEPORELESS FOUNDATION mednow MAYBELLINE MAYBELL AFCEEEE! MAYBELLINE som Pharmacy Users Deserve a Convenience and Technology Upgrade minute clinic ITSX-V: MNOW I OTC-QX: MDNWF laxatives Pharmacy 030 SO 7 900 pick-up Co C pich Archaic Practices that Mednow has Improved "Loss Leader" business model - Pharmacy is not a focus for the largest competitors - Delivery not promoted - Antiquated technologies Fax machines No "on-demand" access - Counting pills by hand - Lack of universal & cloud based medication records 4#5mednow Healthcare5 Education5 Transportation5 Restaurant5 Technology Has Disrupted Many Consumer Industries 2019 Canadian Industry Expenditures ITSX-V: MNOW I OTC-QX: MDNWF $106B $71B Accomodations $8B $21B $264B 99% of Canadians use brick-and-mortar pharmacies² S $47B A 49% of Canadians are open to using virtual pharmacy³ 1 Canadian Retail Pharmacy Market 1. IBISWorld, Pharmacies & Drug Stores in Canada, 2020; this figure represents the total amount spent on this industry in Canada in 2019. 18% Digital pharmacy is tracking for an 18% CAGR4 2. Based on management's current knowledge and reasonable belief. 3. Maru Blu Research 15-minute online survey of 2,564 individuals living in Canada who are 25 years or older and geographically balanced. Surveys were completed between February 26 and March 14, 2022. 4. Cision PR Newswire: ePharmacy Market Size worth $169.3 Billion By 2028. 5. StatsCan, Spending, Canada, 2019. 5 ØST#6mednow DOCTORS 2 1 Mednow is a Full-Service Pharmacy in your Pocket Proprietary Virtual Pharmacy Technology DIGITAL PHARMACY HOLISTIC HEALTH ITSX-V: MNOW I OTC-QX: MDNWF Hi, Ronald. How can we help you? M Do you have a prescription at another pharmacy? If you have an active prescription or available refil our team can transfer them for you Request a Transfer Upload a New Prescription Don't Have a Prescription? See a Clinician D Chat With Our Pharmacy Connects Patients to Mednow Licensed + Owned Pharmacy Distribution Network what the spring fee 0 Orders ❤ 4 TE 18 16 Customers Access Health Ecosystem Dato 3 Quick, Free Prescription and Medication Delivery wonbam worloem (28-430 6#7mednow Easily Sign Up & Access Care < Login 1% Account Personal Thank you for signing up! Thank you for registering with Mednow. Please check you email to activate your account. ITSX-V: MNOW I OTC-QX: MDNWF Customer Obsessed and Amazing Patient Experience is our DNA Speak with Care Professionals on Demand < Back 16 How can we help you? Questions about my order Medication or Health Advice Chat History General questions for Mednow > > Disease Specific Programs What health problems are you facing? Help us help you Chronic headaches Stomach pain Dry skin Other Check Ins/ Reminders 9:41 MEDNOW thago Mayat Hey there! Just checking in to see how your medication plan is going? Free Delivery Delivery mednow Same Day Delivery Deliver tomorrow Deliver in 2-5 days Ø 7#8mednow Direct-to-Patient Seamless product experience Mednow Seeks to Solve Important Problems for our Customer Base ITSX-V: MNOW I OTC-QX: MDNWF Business-to-Business mednow for business Help employers to better manage their drug benefit expenditure Enable employers to provide wellness and digital health programs to employees Prescribers Add administrative, time and clinical value to prescriber groups 1. Google Reviews, as at October 1, 2022 8 Di#9Payors ¹, 2 1, ● ● Pharmacy is a significant cost for health benefits providers in Canada - costs need to be controlled High demand for corporate wellness services that prioritize wellness, cater to remote/hybrid work What is Mednow for Business? A Convergence of Forces has Led to Increased Demand for a Digital Pharmacy from Organizations • Early days of digital preferred pharmacy network adoption in Canada post-pandemic Patients 1,2 • Consumers want more convenient, transparent and private pharmacy solutions • According to a recently completed study, Canadians have expressed being open to using a virtual pharmacy • Digitization in pharmacy is in its infancy mednow ITSX-V: MNOW I OTC-QX: MDNWF a Hi, Anna. How can we help you? Upload a new prescription Do you need a prescription? ✓ Transfer a prescription to Mednow clinician ma O 0 > Manufacturers National Speciality Pharmacy division focuses on high cost drugs such as biologics • Two specialty pharmacy acquisitions strengthen expertise and relationships in this fast-growing class of drugs • Mednow's core infrastructure of a clinical pharmacy network, technology and logistics provides a differentiated offering with few competitors Prescribers 1, 2 ● Prescribers would like better medication adherence support, education and data from a pharmacy partner • Mednow aims to lift admin burdens from clinic operations • Increasing complexity and a shift to virtual care drives demand for a clinically reliable virtual pharmacy partner 1. Maru Blu Research 15-minute online survey of 2,564 individuals living in Canada who are 25 years or older and geographically balanced. Surveys were completed between February 26 and March 14, 2022 2. Based on management's current knowledge and reasonable belief 9#10Estimated Total Addressable Market (TAM)¹ Potential Customer Pool - in late stage negotiations What is Mednow for Business? Mednow for Business has Already Established a Pipeline of Approximately 250K Lives, with an estimated Total Addressable of 26 Million Lives 26 million lives Current Signed Preferred Pharmacy Agreements 550K lives mednow ITSX-V: MNOW I OTC-QX: MDNWF 250K lives³ Employers, Insurance Companies, Advisors & Third Parties Union Groups, Associations Brandname, Generic, Speciality and Device Manufacturers Primary Care Clinics, Specialist Networks, Virtual Care companies Payors www... $ Undisclosed Payors Clinics Manufacturers 0 Undisclosed Clinic Partnerships Undisclosed Patient Support Programs Approximate spend per person in Canada on drugs per Year = $1,162 ² 1.26 million = approximately 23 million people in Canada (60%) are insured through their employer (https://spph.ubc.ca/canadians-spend-more-on-private-health-insurance-for-smaller-payouts/); plus 3 million (20% estimate of public and non-insured Canadians who will be referred to a digital pharmacy by a prescriber) 2. CIHI National Health Expenditure, 2019. 3. # of lives with drug benefits in organizations that have Mednow as preferred pharmacy network (PPN) De 10#11mednow CANADA'S TOP 40 UNDER 40 XIL RxCarePharmacies SHOPPERS DRUG MART Loblaws League CERIDIAN Dayforce Our Management Team has proven their Ability to Scale and Operate World-Class Businesses Ali Reyhany CEO, Director & Co-Founder CEO and Co-Founder, Carepharmacies.ca, 45+ Locations, $150M Revenue.¹,2 BNN Bloomberg and Financial Post "Canada's Top 40 Under 40" 2020. Bachelor of Science - Pharmacy from the University of Toronto. David Marantz Chief Revenue Officer David has 15 years of experience working in sales, strategy and general management at leading HR, benefits and health technology companies, such as Dayforce, Ceridian (NYSE: CDAY) and League. MBA and HBA, in strategy and finance, respectively, from the Ivey Business School at Western University. ITSX-V: MNOW I OTC-QX: MDNWF J.P. Morgan BMO make my trip mphr> ALTUS ASSESSMENTS Ben Ferdinand (CPA, CMA, ICD.D) CFO Former CFO at a publicly traded medical health and wellness company, handling over $300M in acquisitions and raising $70M.¹ Investment banking in New York at JP Morgan (NYSE: JPM) and in Toronto at BMO (TSX: BMO). Served on the boards of CanDeal Inc. and Shorcan Brokers Ltd. MBA from Ivey Business School at Western University. Sim Grewal VP, Technology Computer Science engineer with 13+ years of experience in healthcare technology with a strong focus on execution. Leading the software engineering function at Mednow. Previously, VP Solutions Design at MphRx. 1. Historical financial performance is not indicative of future results. 2. Annualized monthly run-rate as of September 2022 11 Di#12mednow Key Fiscal Q3/22 Highlights Strong Revenue and Patient Growth Continues ITSX-V: MNOW I OTC-QX: MDNWF $6.1M Revenue +225% Q/Q ~23K (April (22) Patients Cash Position is Solid and Margins are Strong $9.4M Cash Balance ~20% Gross Margin¹ 1. Gross margin % is not a standardized financial measure under IFRS, might not be comparable to similar financial measures disclosed by other issuers, should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS and are not necessarily indicative of operating results presented under IFRS. For an explanation of the composition of this non-IFRS ratio and how it provides useful information to an investor please see page 2 of this presentation. 12#13mednow Strong Q3/22 Revenue Growth of +225% Q/Q +360% Growth $124K Fiscal Q4/21 ITSX-V: MNOW I OTC-QX: MDNWF +230% Growth $570K Fiscal Q1/22 +225% Growth $1.9M Fiscal Q2/22 $6.1M Fiscal Q3/22 13#14mednow ITSX-V: MNOW I OTC-QX: MDNWF Active Patients Grew +20% Q/Q 16K Fiscal Q1/22 +20% 19K Fiscal Q2/22 +20% 23K Fiscal Q3/22 14#15Appendix D#16Receives DTC Eligibility Mednow Tru-Diagnostic Virtual Care Exclusive Canadian launch Partnership mednow Development and Milestones in Calendar 2021, 2022 11% Equity Stake LS24/7 Mental Health Q3 2021 Q4 2021 Marketing services agreement with Sterling Capital Brokers Organic growth ITSX-V: MNOW I OTC-QX: MDNWF Mednow Pharmacy West Launch Acquisition of Specialty Pharmacy InfusiCare Canada Inc. Ontario Pharmacy Acquisition (Mednow East Inc.) Purchase Agreement for London Pharmacare Inc. and Liver Care Canada Inc. Inorganic growth Great Place To Work. Certified NOV 20-OCT HIE Q1 2022 Q2 2022 Launch National Marketing Campaign Partnerships Launch Total Health Launch of Licensed Pharmacy in Manitoba Record Fiscal Q2 2022 Results 230% Q/Q Revenue Growth Record Fiscal Q3 2022 Results 225% Q/Q Revenue Growth Speciality Pharmacy Related Mednow Signs Franchise Agreement to Open Quebec Pharmacy Aya Chooses Mednow as Preferred Pharmacy Partner Q3 2022 Q4 2022 Mednow Receives Best Workplaces in Healthcare Honour 16#17mednow General Synergies Infrastructure Synergies Accretive Acquisitions Create Significant Synergies in the Mednow Ecosystem Description Key Metrics - revenue, profits, patients 1 Cross-Selling - more robust offering to win clients and patients National Expansion Technology - integrate into streamlined technology offering Advanced Capabilities -at-home care / specialty pharmacy services People - adds key primary care and specialist physician roster, patient base and industry relationships ITSX-V: MNOW I OTC-QX: MDNWF Medvisit . At-home doctor services ● $3M revenue, -30% gross margin > > > ● InfusiCare Pharmacy that specializes in biologics for rheumatology and gastroenterology ● $9.3M revenue, -10% gross margin ● Liver Specialty Group Pharmacy that specializes in hepatology and the treatment of liver disease . $21.3M revenue, ~10% gross margin 1.2021 fiscal year end ✓ 17 ØST#18Thank You Investor Relations Contact: Ben Ferdinand, CFO [email protected] 1.855.686.6300 https://investors.mednow.ca Dat